Nephrol Dial Transplant (1996) 11: 687-692
© 1996 European Renal Association-European Dialysis and Transplant Association
other
Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor
INSERM Unité 90 and Département de Néphrologie, Hôpital Necker Paris, France
Correspondence and offprint requests to: Correspondence and offprint requests to: Tilman B. Drüeke MD, INSERM Unité 90, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France
BACKGROUND.: The treatment of uraemic patients with recombinant human erythropoietin (rHuEpo) often leads to an increase in blood pressure. Indirect and direct effects of the hormone are probably involved. We explored the possibility of a direct action on the vascular smooth muscle cell (VSMC).
METHODS.: Rat VSMC were isolated from aortas of spontaneously hypertensive rats (SHR) and normotensive control rats (WKY) and maintained in culture. They were exposed to rHuEpo under various experi mental conditions, and cells proliferative index was measured by [3H]-thymidine incorporation. Binding studies and Northern blots were performed in an attempt to identify a specific erythropoietin receptor (EpoR). In the latter experiment, Epo-responsive Rauscher Reds cells (Reds cells) were used as a positive control for mRNA EpoR expression.
RESULTS.: VSMC growth index of SHR was enhanced up to 1.6-fold by rHuEpo concentrations of 16 U/ml or more, in the presence of 1% fetal calf serum. No such stimulation was observed in VSMC of WKY. Binding studies with radiolabelled rHuEpo showed either extremely low or no specific binding of radio-labelled rHuEpo by VSMC. However, Northern blot analysis revealed the expression of EpoR mRNA in VSMC of either rat strain.
CONCLUSION.: The present report provides preliminary evidence in favour of a direct action of the hormone on vascular smooth muscle via a specific EpoR.
Keywords: erythropoietin (Epo); Epo-receptor; vascular smooth muscle; culture; rat; hypertension
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Smith, D. Semple, S. Bhandari, and A.-M. L. Seymour Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail, August 1, 2009; 11(8): 732 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Vaziri and X. J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1082 - 1088. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yokomaku, T. Sugimoto, S. Kume, S.-i. Araki, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Nitta, M. Haneda, D. Koya, et al. Asialoerythropoietin Prevents Contrast-Induced Nephropathy J. Am. Soc. Nephrol., February 1, 2008; 19(2): 321 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lee, J. S. Lee, and J. Y. Lee Prevention of Erythropoietin-Associated Hypertension Hypertension, August 1, 2007; 50(2): 439 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. R. Santhanam, L. A. Smith, K. A. Nath, and Z. S. Katusic In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H781 - H786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Coleman, C. Westenfelder, F. E. Togel, Y. Yang, Z. Hu, L. Swenson, H. G. D. Leuvenink, R. J. Ploeg, L. V. d'Uscio, Z. S. Katusic, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities PNAS, April 11, 2006; 103(15): 5965 - 5970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst Erythropoietin Biology in Cancer Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galeano, D. Altavilla, D. Cucinotta, G. T. Russo, M. Calo, A. Bitto, H. Marini, R. Marini, E. B. Adamo, P. Seminara, et al. Recombinant Human Erythropoietin Stimulates Angiogenesis and Wound Healing in the Genetically Diabetic Mouse Diabetes, September 1, 2004; 53(9): 2509 - 2517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Vesey, C. Cheung, B. Pat, Z. Endre, G. Gobe, and D. W. Johnson Erythropoietin protects against ischaemic acute renal injury Nephrol. Dial. Transplant., February 1, 2004; 19(2): 348 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Henry The Evolving Role of Epoetin Alfa in Cancer Therapy Oncologist, February 1, 2004; 9(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J Smith, A. J Bleyer, W. C Little, and D. C Sane The cardiovascular effects of erythropoietin Cardiovasc Res, September 1, 2003; 59(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ito, E. Kusano, Y. Furukawa, H. Yamamoto, S.-I. Takeda, T. Akimoto, O. Iimura, Y. Ando, and Y. Asano Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells Am J Physiol Cell Physiol, December 1, 2002; 283(6): C1715 - C1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Q. Wang and N. D. Vaziri Erythropoietin Depresses Nitric Oxide Synthase Expression by Human Endothelial Cells Hypertension, March 1, 1999; 33(3): 894 - 899. [Abstract] [Full Text] [PDF]
|
|